{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:23:24Z","timestamp":1783056204148,"version":"3.54.6"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2016,5,1]]},"DOI":"10.1001\/jamadermatol.2015.5547","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T21:34:20Z","timestamp":1452720860000},"page":"513","source":"Crossref","is-referenced-by-count":26,"title":["Transgender Patients, Isotretinoin, and US Food and Drug Administration\u2013Mandated Risk Evaluation and Mitigation Strategies"],"prefix":"10.1001","volume":"152","author":[{"given":"Kenneth A.","family":"Katz","sequence":"first","affiliation":[{"name":"Department of Dermatology, Kaiser Permanente, Pleasanton, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2481420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T21:51:09Z","timestamp":1481925069000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2015.5547"}},"subtitle":["A Prescription for Inclusion"],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2015.5547","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5,1]]}}}